Individualizing dosing of irinotecan

Clinical Cancer Research

Volumn 16, Issue 2, 2010, Pages 371-372

  Ratain, Mark J ^a   Innocenti, Federico ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; AMONAFIDE; CAMPTOTHECIN; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 3A4; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; MIDAZOLAM; ORGANIC ANION TRANSPORTER 2; PREGNANE X RECEPTOR;

BONE MARROW SUPPRESSION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; GENOTYPE; HUMAN; INDIVIDUALIZATION; NEUTROPENIA; NOTE; PHENOTYPE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; HUMANS; INDIVIDUALIZED MEDICINE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 74549135102     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2936     Document Type: Note

References (12)

1. van der Bol JM, Mathijssen RHJ, Creemers GM. A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin Cancer Res 2010;16:736-42.
2. Slatter JG, Schaaf LJ, Sams JP, et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C] CPT-11 in cancer patients. Drug Metab Dispos 2000;28:423-33.
3. Santisteban M, Buckner JC, Reid JM, et al. Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results. J Neurooncol 2009;92:165-75.
4. Ratain MJ, Schilsky RL, Conley BA, Egorin MJ. Pharmacodynamics in cancer therapy. J Clin Oncol 1990;8:1739-53.
5. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-8.
6. Innocenti F, Iyer L, Ratain MJ. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab Dispos 2001;29:596-600.
7. Sanghani SP, Quinney SK, Fredenburg TB, et al. Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis. Clin Cancer Res 2003;9:4983-91.
8. de Jong FA, Mathijssen RH, Xie R, Verweij J, Sparreboom A. Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability. Clin Cancer Res 2004;10:4068-71.
9. Toffoli G, Cecchin E, Gasparaini G, et al. A genotype-driven phase I study of irinotecan administered in combination with 5-fluorouracil/leucovorin (FOLFIRI) in metastatic colorectal cancer patients. J Clin Oncol. In press 2009.
10. Innocenti F, Kroetz DL, Schuetz E, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009;27:2604-14.
11. Ratain MJ, Mick R, Schilsky RL, Vogelzang NJ, Berezin F. Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol 1991;9:1480-6.
12. Ratain MJ. Personalized medicine: building the GPS to take us there. Clin Pharmacol Ther 2007;81:321-2.